Glasgow prognostic score predicts prognosis for cancer patients in palliative settings: a subanalysis of the Japan–prognostic assessment tools validation (J-ProVal) study

Supportive Care in Cancer

Volumn 23, Issue 11, 2015, Pages 3149-3156

  Miura, Tomofumi ^a   Matsumoto, Yoshihisa ^a   Hama, Takashi ^b   Amano, Koji ^c   Tei, Yo ^d   Kikuchi, Ayako ^e   Suga, Akihiko ^f   Hisanaga, Takayuki ^g   Ishihara, Tatsuhiko ^h   Abe, Mutsumi ⁱ   Kaneishi, Keisuke ^j   Kawagoe, Shohei ^k   Kuriyama, Toshiyuki ^l   Maeda, Takashi ^m   Mori, Ichiro ⁿ   Nakajima, Nobuhisa ^o   Nishi, Tomohiro ^p   Sakurai, Hiroki ^q   Morita, Tatsuya ^d   Kinoshita, Hiroya ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d SEIREI MIKATAHARA GENERAL HOSPITAL   (Japan)

^e MITSUBISHI KYOTO HOSPITAL   (Japan)

^f SHIZUOKA SAISEIKAI GENERAL HOSPITAL   (Japan)

^g Tsukuba Medical Center   (Japan)

^h OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

ⁱ Matsue City Hospital   (Japan)

^j TOKYO KOSEI NENKIN HOSPITAL   (Japan)

^k Aozora Clinic   (Japan)

^l WAKAYAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^m TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

ⁿ Gratia Hospital   (Japan)

^o TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^p KAWASAKI MUNICIPAL HOSPITAL   (Japan)

^q ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

more..

Author keywords

Albumin; C reactive protein; Cancer; Glasgow prognostic score; Inflammation; Palliative care; Prognosis

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CORRELATIONAL STUDY; DYSPNEA; EDEMA; FEMALE; GLASGOW PROGNOSTIC SCORE; HUMAN; INDEPENDENT VARIABLE; JAPAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEUTROPHIL LYMPHOCYTE RATIO; PATIENT REFERRAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; SURVIVAL TIME; SYSTEMATIC REVIEW (TOPIC); VALIDATION STUDY; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASMS; PALLIATIVE THERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; VERY ELDERLY;

ALBUMINOID; C REACTIVE PROTEIN; SERUM ALBUMIN;

AGED; AGED, 80 AND OVER; ALBUMINS; C-REACTIVE PROTEIN; COHORT STUDIES; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; PALLIATIVE CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SERUM ALBUMIN;

EID: 84942506375     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2693-x     Document Type: Article

References (28)

1. Morita T, Tsunoda J, Inoue S, Chihara S (1999) The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 7(3):128–133
2. Maltoni M, Caraceni A, Brunelli C, Broeckaert B, Christakis N, Eychmueller S, Glare P, Nabal M, Vigano A, Larkin P, De Conno F, Hanks G, Kaasa S (2005) Prognostic factors in advanced cancer patients: evidence-based clinical recommendations—a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 23(25):6240–6248. doi:10.1200/JCO.2005.06.866
3. Lau F, Cloutier-Fisher D, Kuziemsky C, Black F, Downing M, Borycki E, Ho F (2007) A systematic review of prognostic tools for estimating survival time in palliative care. J Palliat Care 23(2):93–112
4. McMillan DC (2013) The systemic inflammation-based Glasgow prognostic score: a decade of experience in patients with cancer. Cancer Treat Rev 39(5):534–540. doi:10.1016/j.ctrv.2012.08.003
5. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ (2004) Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer 90(9):1704–1706. doi:10.1038/sj.bjc.6601789
6. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O'Reilly DS, Foulis AK, Horgan PG, McMillan DC (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow inflammation outcome study. Eur J Cancer 47(17):2633–2641. doi:10.1016/j.ejca.2011.03.028
7. Jiang X, Hiki N, Nunobe S, Kumagai K, Kubota T, Aikou S, Sano T, Yamaguchi T (2012) Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer 107(2):275–279. doi:10.1038/bjc.2012.262
8. Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Cho SH, Chung IJ (2011) Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. Bmc Cancer 11:489. doi:10.1186/1471-2407-11-489
9. Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, Kubota K, Sharma R (2012) A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol 57(5):1013–1020. doi:10.1016/j.jhep.2012.06.022
10. Partridge M, Fallon M, Bray C, McMillan D, Brown D, Laird B (2012) Prognostication in advanced cancer: a study examining an inflammation-based score. J Pain Symptom Manag 44(2):161–167. doi:10.1016/j.jpainsymman.2011.08.013
11. Baba M, Maeda I, Morita T, Hisanaga T, Ishihara T, Iwashita T ea (2014) Independent validation of the modified Prognosis Palliative care Study (PiPS) predictor models throughout three palliative care settings. Journal of Pain and Symptom Management
12. Stone CA, Tiernan E, Dooley BA (2008) Prospective validation of the Palliative Prognostic Index in patients with cancer. J Pain Symptom Manag 35(6):617–622. doi:10.1016/j.jpainsymman.2007.07.006
13. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124. doi:10.1093/jnci/dju124
14. MacDonald N (2011) Chronic inflammatory states: their relationship to cancer prognosis and symptoms. J R Coll Phys Edinb 41(3):246–253. doi:10.4997/JRCPE.2011.315
15. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, Jatoi A, Kalantar-Zadeh K, Lochs H, Mantovani G, Marks D, Mitch WE, Muscaritoli M, Najand A, Ponikowski P, Fanelli FR, Schambelan M, Schols A, Schuster M, Thomas D, Wolfe R, Anker SD, Boyce A, Nuckolls G (2008) Cachexia: a new definition. Clin Nutr 27(6):793–799. doi:10.1016/j.clnu.2008.06.013
16. Miura T, Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H ea (2014) Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas
17. Mitsunaga S, Ikeda M, Shimizu Y, Ohno I, Fruse J, Inagaki M, Higashi S, Kato H, Terao K, Ochiai A (2013) Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 108(10):2063–2069
18. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC (1990) Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12(5):1179–1186
19. Morrone G, Ciliberto G, Oliviero S, Arcone R, Dente L, Content J, Cortese R (1988) Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J Biol Chem 263(25):12554–12558
20. Young DP, Kushner I, Samols D (2008) Binding of C/EBPbeta to the C-reactive protein (CRP) promoter in Hep3B cells is associated with transcription of CRP mRNA. J Immunol 181(4):2420–2427
21. Sirott MN, Bajorin DF, Wong GY, Tao Y, Chapman PB, Templeton MA, Houghton AN (1993) Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 72(10):3091–3098
22. Fearon KC, Falconer JS, Slater C, McMillan DC, Ross JA, Preston T (1998) Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg 227(2):249–254
23. Ballmer PE, Ochsenbein AF, Schutz-Hofmann S (1994) Transcapillary escape rate of albumin positively correlates with plasma albumin concentration in acute but not in chronic inflammatory disease. Metabolism 43(6):697–705
24. Doweiko JP, Nompleggi DJ (1991) The role of albumin in human physiology and pathophysiology, Part III: albumin and disease states. JPEN J Parenter Enter Nutr 15(4):476–483
25. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495. doi:10.1016/S1470-2045(10)70218-7
26. Wigmore SJ, Plester CE, Richardson RA, Fearon KC (1997) Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer 75(1):106–109
27. Fearon K, Arends J, Baracos V (2013) Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol 10(2):90–99. doi:10.1038/nrclinonc.2012.209
28. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K, Hara M, Taguchi H, Kimura Y, Kato Y, Asaoku H, Kumagai S, Kodama F, Nakahara H, Hagihara K, Yoshizaki K, Kishimoto T (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106(8):2627–2632. doi:10.1182/blood-2004-12-4602